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ABSTRACT
Patients diagnosed with hematology malignancy and solid tumor who underwent chemotherapy, frequently 
encountered hepatitis B reactivation. Patients with blood cancer, including lymphoma, had higher risk of 
reactivation compared to those with solid tumor. Steroid and immunosuppressant drugs contained in chemotherapy 
regimens were responsible for those events. Hepatitis B reactivation during chemotherapy treatment could 
contribute to acute liver failure and increase mortality. Administration of analog nucleoside therapy in this 
group of patient prior to the initiation of chemotherapy could prevent reactivation of hepatitis B.
A 43 year-old male patient were diagnosed with diffuse large B cell non-Hodgkin lymphoma stadium II BE 
(oropharynx) under chemotherapy and had hepatitis B. In this evidence based case report, we reported a critical 
appraisal of the role of lamivudine as preemptive therapy in blood cancer and solid tumor.
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ABSTRAK
Pasien dengan diagnosis dengan keganasan darah dan tumor padat yang menjalani kemoterapi, seringkali 
mengalami reaktivasi dari hepatitis B. Pasien dengan keganasan darah termasuk limfoma, memiliki risiko 
reaktivasi yang lebih tinggi dibandingkan pasien dengan tumor padat. Steroid dan obat imunosupresan  yang 
merupakan bagian dari regimen kemoterapi dapat menyebabkan terjadinya hal tersebut. Reaktivasi hepatitis 
B pada saat menjalani regimen kemoterapi dapat menyebabkan gagal hati akut yang meningkatkan angka 
mortalitas. Pemberian nukleosida analog pada kelompok pasien tersebut dapat mencegah terjadinya reaktivasi 
hepatitis B.
Seorang pasien laki-laki usia 43 tahun didiagnosis dengan penyebaran sel besar B non Hodgkin limfoma 
stadium II BE (orofaring) dibawah kemoterapi dan memiliki hepatitis B. Pada laporan kasus berbasis bukti ini 
dilaporkan hasil telaah kritis peran lamivudine sebagai terapi pre-emtif pada keganasan darah dan tumor padat.
Kata kunci: kemoterapi, reaktivasi hepatitis B, keganasan
INTRODUCTION
More than 350 million people in the world were 
infected by hepatitis B virus (HBV). Chronic HBV 
infection is a main health problem and is the most 
common cause of liver cancer in Asia and Africa. In 
the United States, HBV infection prevalence which 
is defined as the presence of HbsAg in the blood, 
is found less than 1% in population but it is 5-15% 
among immigrants from Asia, Africa, Middle East, and 
Eastern Europe.1 HBV infection may cause chronic 
liver disease, cirrhosis, and liver cancer. While many 
patients had HBV in their serum and hepatocytes 
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for years, only a few showed clinical effects. These 
individuals are considered in hepatitis B surface 
antigen (HBsAg) carrier state and few evidence showed 
presence of liver disease despite the low replication 
rate of HBV in the liver cells. In such individuals, 
immunosuppresive agents may trigger enhancement of 
HBV replication followed by hepatitis B flaring which 
can be severe and fatal.1
Reactivation of HBV infection has been observed in 
several clinical settings such as in liver transplantation, 
partial liver resection in hepatocellular carcinoma, 
pregnancy, and immunosuppresion (either due to 
iatrogenic or infective cause, including chemotherapy 
and HIV infection), immunosuppression withdrawal, 
bone marrow transplantation or even spontaneously.1,2 
The immunosuppresive nature of chemotherapy could 
cause HBV flares in people who has HbsAg in their 
sera. Reactivation may occur despite the normal level 
of ALT and low titer of circulating virus prior to the 
initiation of chemotherapy and eventually would 
increase morbidity and mortality.1,2
In a prospective study, it was obtained that more than 
60% of HBV reactivation took place in HbsAg-positive 
patients receiving cytotoxic therapies. Cytotoxic 
therapy, with or without adjuvant immunomodulator 
therapy, would affect the risk of reactivation. Patients 
with blood cancer, including lymphoma, receiving 
high dose glucocorticoid as part of their chemotherapy 
regiments were considered to have a higher risk of 
reactivation (up to 67%) compared to those who were 
associated with solid tumors (< 40%).2  In cases of HBV 
reactivation during the early phase of chemotherapy, 
cytotoxic therapy should be delayed for 100 days, 
due to the survival rate of patients with malignancy 
complicated by HBV reactivation. Mortality rate 
directly associated with HBV reactivation, which leads 
to acute liver disease, varies from 4-60%.2
CASE ILLUSTRATION
A 43 year-old male patient were diagnosed with 
diffuse large B cell Non Hodgkin Lymphoma stadium II 
BE (oropharynx) under chemotherapy and had hepatitis 
B. He was scheduled to undergo chemotherapy the 
following week. A few years ago, he routinely donated 
his blood to Indonesian Red Cross and was found to 
be HbsAg positive. Other examinations to diagnose 
hepatitis B have never been performed. There was 
no history of multiple partners. He also denied any 
history of nausea, vomiting, upper abdominal pain, 
or jaundice. He never had any episode of vomitting 
of blood, black “tarry” stool, abdominal distension, 
and leg swelling. History of past illness did not reveal 
any history of hypertension, diabetes, cardiovascular 
disease, asthma, allergy, and jaundice. There was also 
no history of similar disease in his family. 
On physical examination, his vital signs were 
within normal limits. There were no pale conjunctiva 
nor icteric sclera. The patient had tracheostomy 
tube. Heart and lung examinations were normal. 
Abdominal examination showed flat abdomen, no 
abdominal tenderness, no liver or spleen enlargement, 
no shifting dullness and normal bowel sound. There 
was no stigmata of cirrhosis such as hair loss, spider 
nevi, caput medusa, venectation, leg swelling, 
palmar erythema, or flapping tremor. Laboratory 
examination revealed normocytic normochromic 
anemia (hemoglobin 8.9 g/dL); slightly increased 
transaminase enzymes (aspartate aminotransaminase 
(AST) 40 U/L and alanin transaminase (ALT) 64 
U/L);  serum iron 17 µg/dL; total iron binding capacity 
(TIBC) 269 mcg/dL; ferritin 729.4 µg/L, HbsAg titer 
4,373.0 IU/mL considered as reactive and anti hepatitis 
C virus (HCV) 0.08 considered as non-reactive. Other 
peripheral blood examination, serum electrolytes, 
kidney function test and blood glucose were within 
normal limits. He was then diagnosed with diffuse large 
B cell non Hodgkin malignant lymphoma stadium II 
B type with oropharyngeal extranodal involvement 
with a plan of chemotherapy using rituximab, cytoxan, 
hydroxydaunorubicin, oncovin, prednisone (R-CHOP) 
on the third cycle complicated by anemia of chronic 
disease and hepatitis B. To the patient, lamivudin 100 
mg was planned to be given daily started from 1 week 
prior to chemotherapy until 3-6 months thereafter.
Clinical Problem
Based on the findings of some studies, lamivudin 
therapy for HbsAg carrier receiving immunosuppresive 
agents or other chemotherapy has shifted from 
therapy after the reactivation had been diagnosed to 
prophylaxis therapy prior to chemotherapy. This has 
become the basis for further evaluation on effectivity 
and safety of lamivudine as preemptive therapy in 
HbsAg carrier, especially in patients with blood cancer 
and solid tumor undergoing chemotherapy.
On that basis, clinical questions arised: “what is the 
role of lamivudine as preemptive therapy in patients 
with blood cancer and solid tumors complicated by 
hepatitis B who undergo chemotherapy?” and “will 
preventive therapy using lamivudin decrease the 
risk of HBV reactivation, hepatitis associated with 
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HBV, liver failure due to HBV or HBV-associated 
death, in patients with positive HbsAg who undergo 
chemotherapy?”
Tracking Method and Result
Literature searching method used to answer the 
clinical question was online literature searching 
using Pubmed search engine. The keywords used 
were ”lamivudine AND preemptive therapy AND 
chemotherapy”, limited by: study on human and 
publication in English.
Using this method, 28 articles which fulfilled 
the criteria were collected. Further searching using 
relevant references were done manually. At the end 
of the literature searching, some relevant articles, 
consisted of clinical trials, were obtained to answer 
these clinical questions. Level of evidence were defined 
based on the classification published by Oxford Centre 
for Evidence-based Medicine Level of Evidence.
Ziakas et al performed a meta-analysis on 95 related 
publications. After the evaluation of relevant and 
conclusive publication data completeness, 9 studies 
that met the criteria were obtained. These studies 
involved 396 people; 127 patients on the prophylactic 
lamivudine arm and 269 patients on the control group. 
Cummulative prevalence of HBV reactivation on the 
prophylactic group was 8.6% (11/127) vs. 50.6% 
(136/269) on the control group. Reactivation incidence 
on patients who did not receive prophylaxis varied 
from 54.5-100% while the incidence of reactivation in 
the prophylactic study group was not more than 5%.3
The largest randomised, prospective study regarding 
lamivudine prophylaxis in non Hodgkin lymphoma 
patients undergoing chemotheraphy showed that 
lamivudine prophylaxis, after multivariate analysis, 
was the only independent factor which could predict 
HBV reactivation (OR = 0.04; 95% CI = 0.005-
0.344). Although HBV reactivation occurred during 
chemotherapy, incidence and severity of hepatitis flare 
reduced significantly.3
Lamivudine prophylactic effects accumulatively 
remained significant on forrest plot in a fixed effect 
model (RR = 0.21; 95% CI = 0.13-0.35) without 
evidence of heterogeneity between studies while 
clinical heterogeneity existed. As for the mortality 
rate, combined effect of 8 studies reported insignificant 
decrease clinically by 15/254 (5.9%) in control 
group and 2/117 (1,7%) in prophylaxis group (RR = 
0.68; 95% CI = 0.19–2.49).3 The conclusion of this 
meta-analysis was prophylaxis using lamivudine 
was associated with significant reduction of HBV 
reactivation (RR = 0.21; 95% CI = 0.13-0.35) and the 
trend of HBV-associated death (RR = 0.68; 95% CI 
= 0.19-2.49). Besides, prolonged time of anti-HBV 
prophylaxis may increase survival rate up to 2.4% in 
HBsAg-positive patients.3
A systematic review conducted by Kohrt et al on 9 
prospective studies and one randomized controlled trial 
(RCT) revealed that the rate of hepatitis among subjects 
receiving lamivudine prophylaxis was between 0-20% 
compared to that of the control group, 33-67%. Among 
patients who received prophylaxis, 0-24% of them 
had HBV reactivation compared to 29-56% in the 
control group. Three reactivation cases were related to 
mortality (one subject received prophylaxis, the other 
two were controls). No patients were excluded from 
the study due to toxicity or emerging mutation resistant 
against lamivudine.2
Lau collected literature from 2002-2006 about 
lamivudine as preemptive therapy and obtained 13 
reports. Meta-analysis of these 13 studies of 702 
HbsAg-positive patients (237 were treated with 
preemptive lamivudine and 465 were controls who 
did not receive lamivudine) showed that incidence 
of hepatitis due to HBV reactivation were 3.3% in 
the treated group and 35% in the control group with 
OR = 0.083; 95% CI = 0.045-0.155; p <  0.0001.4-13 
Therefore, there was a strong believe considering 
beneficial effects of preemptive lamivudine to reduce 
hepatitis due to HBV reactivation in HbsAg patients 
receiving cytotoxic or immunosuppressive therapy. 
However, most of these studies were retrospective 
ones without any control groups who did not receive 
therapy.4-13
Loomba et al performed a systematic review of 
several clinical trials and cohort studies reporting the 
efficacy of prevention against HBV reactivation using 
lamivuding in HbsAg-positive patients who received 
chemotherapy. Additional criteria included minimum 
sample size (> 5 participants in each treatment group) 
and reported data on HBV-related morbidity and 
mortality.14 Fourteen studies (two clinical trials with 
control group and randomization; eight prospective 
cohort studies; and four retrospective cohort studies) 
meta analysis criteria. There were 275 patients in the 
group treated with lamivudine and 475 patients in the 
control group with HBV reactivation as primary end 
point. Using lamivudine, the relative risk of HBV 
reactivation and HBV-associated hepatitis varied 
between 0.00-0.21. There was no patient in the 
lamivudine group developed liver failure associated 
with HBV (0 out of 108 vs. 21 out of 162 patients) 
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and only 4 deaths were caused by HBV (4 out of 208 
patients vs. 27 out of 394 patients) in the lamivudine 
group. Lamivudine was well torelated and no side 
effects was found.14 The conclusion of this systematic 
review was that lamivudine treatment in patients with 
HbsAg positive and will undergo chemotherapy might 
reduce the risk of HBV reactivation and HBV-related 
morbidity and mortality.14
Hui et al evaluated the proposed duration of 
preemptive therapy using lamivudine. In a study 
of 46 patients with HbsAg positive who received 
preemptive lamivudine, the therapy was started 1 
week prior to chemotherapy and was continued during 
chemotherapy. Preemptive lamivudine was stopped 
with a median of 3.1 months (range 3-3.4) after 
chemotherapy. These patients were then observed after 
cessation of lamivudine with median duration of follow 
up 25.7 months (range 5.7-75.7).15 
Eleven patients out of 46 (23.9%) developed HBV 
reactivation after lamivudine was stopped. Eight out 
of 16 patients with high copies of HBV DNA prior to 
chemotherapy (> 104 copies/mL) had HBV reactivation 
(50% vs. 10%; p = 0.001). HbeAg-positive patients 
were more probable to have HBV reactivation (5/11 
(45%) vs. 6/35 (17.1%); p = 0.041). Patients with high 
copies of HBV DNA prior to chemotherapy were the 
most important risk factor to develop HBV reactivation 
after the cessation of lamivudine preemptive therapy 
on proportional hazards Cox analysis (RR = 16.13; 
95% CI = 99-87; p = 0.001).15
Kim et al conducted a study to foresee the long term 
effects of lamivudine therapy in prevention of HBV 
reactivation and HbeAg-related morbidity. Twenty four 
patients with non Hodgkin malignant lymphoma were 
given lamivudine 100 mg daily prior to initiation of 
chemotherapy. Treatment duration was approximately 
11.5 months, ranging from 1-54 months, and the 
median of chemotherapy cycles was 6 (range 1-16 
cycles). Chemotherapy regimens using steroid were 
used in 18 (75%) patients and anti CD-20 monoclonal 
antibody was used in 6 (25%) patients.16 
The result was that hepatitis associated with HBV 
reactivation emerged in 1 out of 14 patients with 
positive HbeAg and none occurred in 10 patients 
with negative HbeAg. One patient developed HBV 
reactivation after lamivudine cessation and 4 patients 
had YMDD mutation (tyrosine-methionine-aspartate-
aspartate) during lamivudine treatment. There was no 
statistically significant difference of HBV reactivation 
during chemotherapy based on HbeAg status. It was 
concluded that lamivudine should be considered as 
preemptive treatment prior to chemotherapy in every 
patients with non Hodgkin malignant lymphoma to 
prevent HBV reactivation regardless of HbeAg status 
before chemotherapy.16
DISCUSSION
Cancer is the cause of death in the United States, 
where most people undergo chemotherapy throughout 
their lives. Therefore, though the prevalence of HbsAg 
carrier is low, prevention of HBV reactivation due to 
chemotherapy becomes an important medical problem 
and attention in health sector. This problem becomes 
more important in some parts of the world where HBV 
infection was endemic.2,14
Lamivudine is nucleoside analog which effectively 
suppresses HBV replication and decreases the level 
of HBV DNA in the serum and improve liver injury 
in patients with chronic hepatitis B. Lamivudine also 
has good long term safety profile and in general can 
be well tolerated. Several studies reported the benefit 
in preventing HBV reactivation and death caused by 
HBV in HbsAg positive patients and will undergo 
chemotherapy.14
Initial report of lamivudine revealed that it 
might cause suppression in HBV replication due to 
early termination of DNA chain, which seemed to 
be promising for chronic hepatitis B therapy. In in 
vitro studies, lamivudine has relatively lower profile 
of side effects without significant hematopoetic 
toxicity in HBV reactivation after chemotherapy or 
immunosuppression.2
First clinical trial reported suppression and decrease 
of HBV DNA serum in chronic hepatitis B patients 
and also acute. Previously, series of cases have shown 
the efficacy of lamivudine in treating HIV infected 
patients who had been coinfected with hepatitis B. 
Other series of case reports also showed the evidence 
that in vivo lamivudine is effective in the treatment 
of HBV infected patients who are immunosuppressed 
and safe for patients with chemotherapy associated 
cytopenia. Role of lamivudine in the treatment of 
HBV reactivated was further reported on 2 studies, 
which were reactivation of hepatitis fulminant case 
after chemotherapy in lymphoma and acute jaundice 
hepatitis in allogenic bone marrow transplant patients 
who receive immunosuppression.2
Although lamivudine response were seen in 
most patients, 18-40% patients did not improve by 
lamivudine therapy. Profile between patients who 
failed to respon to lamivudine were because they 
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started lamivudine therapy late. Based on these 
findings, therapy for chronic HbsAg carrier who 
receive immunosuppressive agents or chemotherapy 
has shifted from therapy after reactivation is diagnosed 
to prophylaxis before initiation of chemotherapy.2,14
Early case report on primayr prophylaxis was 
included 20 patients with blood malignancy and variety 
chemotherapy regimens, most of which included 
glucocorticoid. With 5% reactivity rate of HBV, 
lamivudine role in prophylaxis among HbsAg carrier 
had been indicated. However, following study stressed 
on the possibility of lamivudine-resistent mutant and 
increased mortality among some patients which was 
treated with lamivudine.2
In the result of first search study, a meta-analysis 
conducted by Ziakas et al obtained 9 relevant studies and 
with the meta-analysis result as depicted, it was obtained 
the result that supported previous studies; that all 
patients diagnosed with lymphoma should undergo HBV 
screening. All HbsAg carriers should have received 
preemptive antiviral therapy during maintanance phase 
of chemotherapy. Strategies to prolong prophylaxis will 
increase survival rate through decreased reactivation of 
HBV and HBV associated mortality.3
Meanwhile, results of second search from a systematic 
analysis performed by Kohrt et al concluded that 
decreased up to four to seven fold in terms of hepatitis 
and hepatitis B virus reactivation in patients receiving 
lamivudine. Thus, it is recommended that all HbsAg 
carrier patients received lamivudine or antiviral which 
was equal as prophylaxis before chemotherapy initiation 
until, at least, one year after chemotherapy is completed. 2
Based on a level 3 evidence, in year 2004 American 
Association for the Study of Liver Disease (AASLD) 
recommended continuation of prophylactic lamivudine 
up to 6 months after chemotherapy is completed and is 
prolonged in 2007 update for patients with high basis 
of HBV DNA (defined by serum HBV DNA > 2,104 
copies/mL). Then, in year 2009 AASLD recommended 
that antiviral prophylactic therapy should be given 
in hepatitis B carrier (regardless the previous HBV 
DNA level) during initiation of chemotherapy or 
immunosuppressive therapy with limited time and was 
maintained for 6 months after it.17
Viral relapse after discontinuation of lamivudine 
has been reported in patients with high level of HBV 
DNA before chemotherapy, HbsAg positive with HBV 
DNA serum level > 2,000 IU/mL before initiation of 
chemotherapy should have continued the antiviral 
therapy until treatment target as for chronic hepatitis 
B patients is reached. In patients whose level of HBV 
DNA < 2,000 IU/mL, they should have continued 
therapy until 6 months after discontinuation of 
chemotherapy or immunosuppression. Lamivudine or 
telbivudine can be used if the duration of therapy is 
short (< 12 months) and level of serum HBV DNA is 
not detected. Tenofovir or entecavir is more preferred 
if the duration of therapy is longer. Interferon should 
be avoided due to its suppression effect to the bone 
marrow.17
A recommendation issued by Canadian Society 
stated that each patients who will undergo chemotherapy 
or bone marrow transplantation should be tested for 
HBV marker prior to the treatment. For those who 
are HbsAg-positive, preemptive lamivudine therapy 
should be applied to prevent hepatitis flares which may 
take place during the treatment. Since hepatitis flares 
occured as the result of immune recovery, lamivudine 
therapy should be initiated several days prior to 
induction of immunosuppressive therapy.18
Meanwhile, European Association for the Study 
of the Liver (EASL) recommendation of preemptive 
therapy before immunosuppression or chemotherapy is 
for all HBV carrier patients who received chemotherapy 
or immunosuppression due to high reactivation risk, 
particularly if rituximab is given alone or combined 
with steroid. HBV vaccination in seronegative patients 
is highly recommended. EASL also recommends 
to examine HBV DNA level before chemotherapy 
initiation and receive preemptive therapy during therapy 
(regardless of HBV DNA level) and for 12 months after 
cessation of chemotherapy.19 EASL recommendation 
for negative HbsAg patients with positive anti-HBC 
and undetected serum HBV DNA who will receive 
chemotherapy and or immunosuppression should be 
followed-up for ALT and HBV DNA examination 
and treated during positive HBV reactivation before 
elevation of ALT.19
The Asian Pasific Association for the Study of the 
Liver (APASL) recommendation states that lamivudine 
is effective in preemptive therapy in cancer patients 
who will undergo chemotherapy starting in 1 week 
before chemotherapy is started and continued to at least 
12 weeks after chemotherapy was completed and after 
leucocyte count is back to normal.20
Consensus of Indonesian Association for the 
Study of the Liver for chronic hepatitic B infection 
in 2006 also recommended lamivudine therapy 
before administration of immunosuppresive agent or 
chemotherapy which is then continued up to at least 
6 weeks after treatment is proven to be effective in 
preventing reactivation.21
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Patients with blood malignancy and solid tumors 
who will undergo chemotherapy should have been 
examined for their HBV status, which is HbsAg status 
for initial examination. If positive HbsAg was obtained 
and patient will undergo chemotherapy, administration 
of lamivudine as preemptive therapy has been proven 
in many studies for its effectivity in decreasing HBV 
reactivation risk, HBV associated hepatitis, liver 
failure or even survival. Regarding administration 
time, several studies agree to be administered a week 
before chemotherapy was started. In terms of duration 
of lamivudine prophylaxis administration, some 
studies vary and even recommendation for America, 
Europe or Asia Pacific are between 3-12 months after 
chemotherapy is completed. 
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